Tuesday, June 21, 2005

Keep your eye on pSivida

pSivida is one company I'm going to continue to keep an eye on over the years. I've spoken to Roger Aston, director of research and commercialisation (or commercialization, for those of you who do not speak Australian), a couple of times, and each time I grow more impressed with the company.

I'm not only talking about its biodegradable drug delivery technology, which appears to avoid the toxicity problems associated with its nanoscale cousins, buckyballs, dendrimers et al. For the longer term, this company also appears to have a clear plan to travel around the world to our shores, infiltrate our cancer wards, prolong some lives, and then slowly start to scare the living daylights out of us.

Is the United States ready for implantable microchips that your doctor can set to deliver drugs, monitor, control and disintegrate from the comfort of his golf cart? I don't know, but it will be interesting to follow.

(Incidentally, I'm not an investor in this company. Hell, I don't have any spare change to gamble on any company.)

PSivida Reports Findings In Phase IIa Cancer Drug Trials (Dow Jones)

    "Australia's pSivida Ltd. (PSDV) said Tuesday it has composed a final report on the company's Phase IIa clinical trials with BrachySil as a potential new brachytherapy treatment for inoperable primary liver cancer.

    According to a press release contained in a regulatory filing with the Securities and Exchange Commission, the global nanotechnology company said the report confirms that the primary endpoint of the trial was achieved in its key first indication in that BrachySil (32-P BioSilicon) was found to be both safe and well tolerated.

    BrachySil is a micron-sized nanostructured silicon particle in which radioactive 32-phosphorus (32-P) is immobilized. It is administered as a liquid suspension through a fine-gauge needle directly into tumors, the filing said. The procedure takes place under local anaesthetic and without the need for shielded rooms or robotic injectors, and patients can be discharged the next day." More here

Related News
pSivida Initiates R&D Collaboration With University Of South Australia (PR, via BioSpace)

pSivida's biosilicon does its job, then goes away
Bigger bucks for better metaphors
Pint-size pushers

No comments: